Life Sciences finance executives gather in Philadelphia to tackle the challenges and complexities of gross-to-net
PHILADELPHIA, PA – November 20, 2013 – Model N, Inc. (NYSE: MODN), a leading revenue management solutions provider to the life science and technology industries, will present today at CBI’s 3rd Annual Gross-to-Net Accounting & Accruals conference, currently running in Philadelphia. This year’s conference is the go-to forum on the latest forecasting, accounting, and accrual methods being implemented throughout the life sciences industry.
Model N Vice President of Product Management, Ajay Dawar, will present (Wednesday, Nov. 20 at 2:20 p.m. EST) in the track on practical applications for gross-to-net forecasting, calculations, and reporting. Dawar’s presentation “Best Practices to Achieve Price Transparency: A Tale of Two Gross-to-Nets” will explore how two industry leaders, one a med-tech company and the other a global pharma company, effectively employed reliable, repeatable gross-to-net visibility into their organizations. Attendees of this session will learn new ways to overcome change management challenges, how to obtain and leverage executive buy-in, and mistakes to avoid when taking on increased gross-to-net visibility efforts.
“Having complete visibility into your business is the holy grail in life sciences business management,” said Ken Pulverman, vice president of marketing at Model N. “We are pleased to be delivering these solutions today, and are really looking forward to highlighting two customer success stories at one of the largest gross-to-net conferences of the year.”
Model N is a proud sponsor of CBI’s 3rd Annual Gross-to-Net Accounting & Accruals conference, and will be exhibiting in the Regency Foyer at the Loews Hotel in Philadelphia, November 19-20.
Revenue Management for Pharmaceutical Companies
Revenue Management for Medical Device Companies
About Model N
Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Amgen, Atmel, Boston Scientific, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: www.modeln.com. Model N is traded on the New York Stock Exchange under the symbol MODN.
Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.